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Abstract
Introduction: Endothelial barrier breakdown is a hallmark of septic shock, and proteins that physiologically
regulate endothelial barrier integrity are emerging as promising biomarkers of septic shock development. Patients
with cancer and febrile neutropenia (FN) present a higher risk of sepsis complications, such as septic shock.
Nonetheless, these patients are normally excluded or under-represented in sepsis biomarker studies. The aim of our
study was to validate the measurement of a panel of microvascular permeability modulators as biomarkers of
septic shock development in cancer patients with chemotherapy-associated FN.
Methods: This was a prospective study of diagnostic accuracy, performed in two distinct in-patient units of a
university hospital. Levels of vascular endothelial growth factor A (VEGF-A), soluble fms-like tyrosine kinase-1 (sFlt-1)
and angiopoietin (Ang) 1 and 2 were measured after the onset of neutropenic fever, in conditions designed to
mimic the real-world use of a sepsis biomarker, based on our local practice. Patients were categorized based on
the development of septic shock by 28 days as an outcome.
Results: A total of 99 consecutive patients were evaluated in the study, of which 20 developed septic shock and
79 were classified as non-complicated FN. VEGF-A and sFlt-1 levels were similar between both outcome groups. In
contrast, Ang-2 concentrations were increased in patients with septic shock, whereas an inverse finding was
observed for Ang-1, resulting in a higher Ang-2/Ang-1 ratio in patients with septic shock (5.29, range 0.58 to 57.14)
compared to non-complicated FN (1.99, range 0.06 to 64.62; P = 0.01). After multivariate analysis, the Ang-2/Ang-1
ratio remained an independent factor for septic shock development and 28-day mortality.
Conclusions: A high Ang-2/Ang-1 ratio can predict the development of septic shock in cancer patients with
febrile neutropenia.
Introduction
Septic shock is one of the most severe complications of
sepsis, frequently preceding multi-organ dysfunction
syndrome and death. Cancer patients are at an increased
risk of sepsis complications for several reasons, includ-
ing the need for frequent invasive procedures, the effects
of cancer on nutritional status and immunity, and the
immunosuppressive effects of chemotherapy [1]. As life
expectancy increases, so does the prevalence of age-
related morbidities, such as cancer, considered one of
the most important contributing factors for the increas-
ing incidence of sepsis [2]. In this context, the discovery
and validation of new biomarkers for septic shock devel-
opment is regarded as a major research objective in the
field [3,4]. However, the implementation of a biomarker
usually involves a stepwise process, in which results
from initial studies need to be confirmed in larger stu-
dies in independent populations, ideally performed in
experimental environments that more closely resemble
the “real-world” use of the biomarker [3,5].
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In the last decade, the cellular and molecular
mechanisms that regulate endothelial barrier integrity
have been described [6]. In the embryo, VEGF-A, sFlt-
1, angiopoietin (Ang)-1 and Ang-2 play critical roles in
the physiological process of angiogenesis, during which
the endothelial barrier is constantly assembled and dis-
assembled, to allow the incorporation of new vessel
sprouts. While VEGF-A and Ang-2 are involved in the
destabilization of endothelial cell junctions, sFlt-1 and
Ang-1 present distinct functions, stabilizing the
endothelial barrier. After the initial demonstration that
the mechanisms that regulate endothelial barrier for-
mation in the embryo are also involved in the patholo-
gical disruption of the endothelial barrier in adults
during sepsis [7], several studies explored the role of
these proteins as biomarkers of septic shock develop-
ment. Encouraging results were reported by several
groups, and Ang-1 and Ang-2 emerged among the
most promising endothelial-associated sepsis biomar-
kers [8-19].
Patients with cancer and febrile neutropenia (FN) are
one of the populations with the highest risks of sepsis-
related mortality [20,21]. In these patients, septic shock
can evolve as a fulminant complication, despite aggres-
sive treatment with broad-spectrum antibiotics and best
supportive care. Nevertheless, these patients are usually
excluded or largely underrepresented in studies about
sepsis biomarkers and management. In a small explora-
tory study, we previously demonstrated that levels of
modulators of endothelial permeability, such as VEGF-A
and Ang-2 were altered in patients with FN that devel-
oped septic shock [22,23]. In the present work, we
sought to validate the use of VEGF-A, sFlt-1, Ang-1 and
Ang-2 levels as biomarkers of septic shock development
in a larger and independent cohort of patients with can-
cer-associated FN, in a more clinically relevant scenario
regarding the use of a sepsis biomarker.
Material and methods
Patients
The study was conducted at the Hematopoietic Stem
Cell Transplantation and at the Hematology in-patient
units of University of Campinas between March 2011
and March 2012. The study was performed in accor-
dance with the Declaration of Helsinki, and approved by
the Committee of Ethics in Research of the Faculty of
Medical Sciences, University of Campinas, Campinas,
SP, Brazil. Written informed consent was obtained from
all patients prior to any study procedure. Inclusion cri-
teria were: (1) fever (T ≥38°C) over a one-hour observa-
tion period, (2) chemotherapy-induced severe
neutropenia, characterized by an absolute neutrophil
count <0.5 × 109/L at the time of fever onset, and (3)
persistence of severe neutropenia until the time of blood
sample collection. Demographic and clinical data were
obtained from the medical records.
Sepsis definitions and clinical scores
In accordance with FN management protocols, an infec-
tious etiology was assumed for all patients with post-
chemotherapy neutropenia with new onset of fever [24].
Blood and urine cultures were immediately obtained
and broad spectrum antibiotics initiated, along with the
infusion of 1.5 L of intravenous saline solution over
each 24-hour period. All patients underwent chest
radiography. Other imaging studies were performed
when judged necessary by the attending physician. Sep-
sis was defined by the presence of two or more of the
following: (1) temperature >38°C, (2) heart rate >90
beats/minute, (3) respiratory rate >20 breaths/minute or
PaCO2 <32 mmHg, and a microbiologically proven or
clinically evident source of infection. A diagnosis of sep-
tic shock was established when sepsis-induced hypoten-
sion (systolic arterial pressure <90 mmHg or dropping
>40 mmHg from baseline) persisted despite adequate
volume resuscitation. Volume resuscitation consisted of
30 ml/Kg of crystalloids (usually 2 L) in a bolus fashion
over 60 minutes, targeted to a mean arterial pressure
above 65 mmHg. Failure to achieve this target within
one hour established the diagnosis of septic shock [25].
Severity of illness was assessed by calculating the
Sequential Organ Failure Assessment (SOFA) score [26],
and FN risk stratification was performed by calculation
of the Multinational Association for Supportive Care In
Cancer (MASCC) score [27]. Both scores were calcu-
lated at the time of sample collection.
Study design
This was a prospective non-interventional study per-
formed according to the STARD (Standard for the
Reporting of Diagnostic Accuracy Study) guidelines [28].
All in-patients from the hematology or from the bone
marrow transplantation units with new onset FN that
met the inclusion criteria were invited to participate.
The study was deliberately designed to mimic the condi-
tions in which a sepsis biomarker would be used.
Patients were enrolled in the study within 24 hours
from admission for FN treatment, and samples were
drawn with the next routine sample collection requested
for them (usually in the morning after enrollment).
Furthermore, samples were collected and initially pro-
cessed by the hospital laboratory staff using the same
operational procedures used for other patients. Finally,
neither the prior use of antibiotics, nor the time elapsed
from fever onset until blood draws were considered
exclusion criteria for the study, as long as the patients
remained with severe neutropenia at the time of sample
collection. As per local protocol, the first routine sample
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collection requested for all admitted FN patients
includes a complete blood count (in which the persis-
tence of severe neutropenia was confirmed) and C-reac-
tive protein (CRP) measurement.
Serum levels of VEGF-A, sFlt-1, Ang-1 and Ang-2
were measured by an individual blinded to patient out-
comes, in duplicate, using commercial enzyme linked
immunosorbent assay (ELISA) kits (Quantikine, R&D
Systems, Minneapolis, MN, USA) according to the man-
ufacturer’s instructions. Samples were centrifuged at
1,000 g (4°C, 15 minutes) and serum was stored at -80°
C until analysis. The sensitivities of the assays for
VEGF-A, sFlt-1, Ang-1 and Ang-2 were 9 pg/ml, 3.5 pg/
ml, 3.4 pg/ml and 8.3 pg/ml, respectively. The intra-
and interassay coefficients of variation of all tests were
within the range informed by the manufacturer (range
2.4% to 10.4%). Based upon a power analysis, and con-
sidering an expected rate of septic shock of 25% (from
our previous study), a sample size of 100 patients would
produce at least 80% power at the 0.05 level of signifi-
cance to detect an effect-size of 1 SD in all four assays
between study groups.
Statistical analysis
The primary endpoint of the study was development of
septic shock at any time point before the resolution of
FN or at a maximum of 28 days after enrollment (in
cases of prolonged neutropenia). Based on this outcome,
patients were divided in two groups for the analysis: (i)
non-complicated FN or (ii) septic shock. Differences in
continuous variables between patients from each sub-
group were analyzed using the Mann-Whitney test.
Categorical variables were compared using the Fisher’s
exact test. Data are expressed as median and range
unless otherwise stated. Correlation (Spearman’s rank
correlation) analysis was performed between sepsis
severity scores and biomarker levels. Receiver operator
characteristics (ROC) procedures were used to identify
optimal cut-off values of biomarker concentrations to
differentiate distinct outcome groups. To evaluate the
effect of the Ang-2/Ang-1 ratio as a continuous variable
on the risk of septic shock development and sepsis-
related mortality, a Cox proportional-hazards model was
used assuming a graded relation between the ratio and
either outcome. To evaluate whether there was a non-
linear association between the risk of septic shock and
the Ang-2/Ang-1 ratio, a binary logistic regression
model was used, in which the ratio was dichotomized by
the median and by an optimal cut-off. All multivariate
analysis models were adjusted for covariates with a P-
value <0.10 in univariate analysis. Variables from the
SOFA score were evaluated individually, to avoid the
influence of chemotherapy-induced thrombocytopenia
on the assessment of organ failure. Survival curves were
estimated using the Kaplan-Meier method. A P-value
less than or equal to 0.05 was considered statistically
significant. All statistical analysis were performed with
the SPSS package v. 17.2 (SPSS, Inc., Chicago, IL, USA)
and the GraphPad Prism Software (GraphPad Prism
Software, Inc., San Diego, CA, USA).
Results
Patients’ characteristics
One-hundred twenty patients with FN were identified in
both in-patient units during the study period. All
patients agreed to participate, but only the 99 patients
that met all inclusion criteria were maintained in the
study. Twenty-one patients were excluded because the
absolute neutrophil count had increased to above 0.5 ×
109/L at the time of sample collection (Figure 1). Of
note, none of these 21 patients developed septic shock.
Of the 99 episodes of FN, 20 (19.8%) evolved to septic
shock, and 17 (16.8%) were fatal. All deaths were attrib-
uted to complications of septic shock, and occurred
after a median of 13 days from sample collection (range
3 to 28). Seventy-eight FN episodes (78.8%) were classi-
fied as high-risk FN, based on a MASCC score ≤21 [29].
There were no significant clinical and demographic dif-
ferences between patients with non-complicated FN and
septic shock with respect to age, diagnosis, MASCC
score, CRP, neutrophil and platelet counts, nor any of
the components of the SOFA score. A higher SOFA
score in patients that developed septic shock was the
only significant difference observed at baseline between
the two outcome groups (Table 1). The median time to
septic shock development after sample collection was
three days (range 1 to 17, interquartile range 4.5). In
total, five patients developed septic shock more than
Figure 1 Study flowchart.
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seven days after fever onset. In four of them, septic
shock was associated with probable or proven invasive
fungal infections. In addition, three patients developed
septic shock between enrollment and sample collection,
within 12 hours from blood draw.
Serum levels endothelial permeability modulators
according to the development of septic shock
No statistically significant difference could be detected
between VEGF-A and sFlt-1 levels in patients with non-
complicated FN compared to patients that developed
septic shock (Figure 2). Serum concentrations of Ang-1,
an endothelial barrier-stabilizing factor, were higher in
patients with non-complicated FN (1,220.0 pg/ml, range
32.5 to 47,924.0 pg/ml) than in patients with septic
shock (898.8 pg/ml, range 77.9 to 5,420.0 pg/ml),
although this difference did not reach statistical signifi-
cance (Mann-Whitney test, P = 0.07) (Figure 2). Levels
of Ang-2, an endothelial barrier-destabilizing factor,
were higher in patients that developed septic shock
(6,494.0 pg/ml, range 1,730.0 to 49,611.0 pg/ml) com-
pared to patients with non-complicated sepsis (4,467.0
pg/ml, range 1,289.0 to 37,318.0 pg/ml; Mann-Whitney
test: P = 0.02) (Figure 2).
In addition to these findings, serum levels of Ang-1
presented a negative correlation with the SOFA score
(Rs = -0.36; P = 0.0002) and serum levels of Ang-2 a
positive correlation with CRP (Rs = 0.3; P = 0.002). No
correlation could be observed between platelet counts
and Ang-1 (Rs = 0.1; P = 0.34) or Ang-2 (Rs = 0.1; P =
0.34) levels. Interestingly, when only patients with a pla-
telet count below the median were evaluated, a signifi-
cant correlation between Ang-1 and platelet count could
be observed (Rs = 0.36; P = 0.007).
The Ang-2/Ang-1 ratio is increased in patients with FN
neutropenia that will develop septic shock compared to
patients with non-complicated FN
Because of their antagonistic roles for endothelial barrier
integrity, the relative concentrations of Ang-1 and Ang-
2, expressed as the Ang-2/Ang1 ratio, has been consid-
ered a more relevant sepsis biomarker than isolated
levels of each factor. In fact, the Ang-2/Ang-1 ratio was
much higher in the septic shock outcome group (5.3,
range 0.6 to 57.1) compared to patients with non-com-
plicated FN (1.9, range 0.1 to 64.6; Mann-Whitney test:
P = 0.01) (Figure 3).
Estimation of the diagnostic accuracy of the Ang-2/
Ang-1 ratio for the development of septic shock yielded
an area under the ROC curve of 0.68 (95%CI = 0.55 to
0.81; P = 0.01). An Ang-2/Ang-1 ratio of 5.0 was the
optimal cut-off value identified by the ROC procedure,
with a sensitivity of 60% (95% CI = 36.1% to 80.9%) and
a specificity of 77.2% (95% CI = 66.4% to 85.9%) for the
development of septic shock. The positive and negative
predictive values were 47% and 85%, respectively. Of
note, the estimated diagnostic accuracy of the Ang-2/
Ang-1 ratio was higher than that obtained with either
Table 1 Patient characteristics
Non-complicated FN (n = 79) Septic shock (n = 20) P
Gender (male: female) 44:35 12:8 NS**
Age (median, range) 49 (13 to 78) 52 (21 to 78) NS**
Diagnostic NS**
Acute leukemia 30 10
Other hematolgical malignancies 49 10
Comorbidities (present:absent) 29:40 8:12 NS**
Treatment NS**
Intensive CTx/autologus HSCT 62 15
Allogeneic HSCT 17 5
Neutrophils/µl (median, range) 80 (0 to 500) 0 (0 to 500) NS*





Agent isolation in bloodstream*** (yes:no) 27:52 7:13 NS**
C reactive protein mg/dl (median, range) 11.20 (0.55 to 58.30) 12.7 (6.2 to 40.90) NS*
SOFA score (median, range) 4 (0 to 8) 4 (2 to 14) P <0,05*
MASCC score (median, range) 19 (12 to 23) 18 (12 to 21) NS*
Time to sample collection hours (median, range) 48 (3 to 120)
Time to septic shock days (median, range) 3 (1 to 17)
CTx, chemotherapy; HSCT, hematopoietic stem cell transplantation; MASCC, Multinational Association for Supportive Care in Cancer; SOFA, Sequential Organ
Failure Assessment; * Mann-Whitney test; ** Fisher’s exact test; *** Gram-negative: Acinetobacter baumannii, Enterobacter cloacae, Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia. Gram-positive: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus viridans,
Staphylococcus warneri, Staphylococcus haemolyticus. Fungi: Aspergillus e Fusarium.
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Ang-1 or Ang-2 levels alone, as well as that of CRP,
SOFA or the MASCC scores (Table 2).
An Ang-2/Ang-1 ratio above 5.0 is an independent factor
for the development of septic shock and sepsis-related
mortality in patients with FN
When the Ang-2/Ang-1 was analyzed as a continuous
variable in a Cox proportional-hazards model, the
Figure 2 Vascular permeability-related biomarkers in FN patients. Serum concentrations of soluble fms-like tyrosine kinase-1 (sFlt-1),
vascular endothelial growth factor-A (VEGF-A) and angiopoietin (Ang) -1 and Ang-2 in patients with non-complicated febrile neutropenia (FN)
(n = 79) or septic shock (n = 20). Horizontal bars represent median values; Mann-Whitney test.
Figure 3 Ang-2/Ang-1 ratio in FN patients. Angiopoietin- (Ang)-
2/Ang-1 ratio in patients with non-complicated febrile neutropenia
(FN) (n = 79) or septic shock (n = 20). Horizontal bars represent
median values; Mann-Whitney test.





SOFA 0.65 0.52 to 0.79 0.03
MASCC 0.59 0.45 to 0.74 0.19
C reactive protein 0.59 0.46 to 0.73 0.19
VEGF-A 0.60 0.46 to 0.74 0.15
SFlt-1 0.57 0.43 to 0.72 0.29
Ang-1 0.63 0.49 to 0.76 0.08
Ang-2 0.66 0.53 to 0.79 0.03
Ang-2/Ang-1 ratio 0.68 0.55 to 0.81 0.01
*AUC, area under the ROC curve
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relative risk of septic shock was 1.06 (95% CI 1.02 to
1.10; P = 0.004), even after adjustment for neutrophil
and platelets counts. Other variables, including age, sex,
baseline diagnosis, treatment type and CRP, among
others, were not associated with the risk of septic shock
development in our population. This first analysis
assumed that the association between the Ang-2/Ang-1
ratio and the risk of septic shock development presented
a graded relation. We next evaluated whether there was
a threshold level of the Ang-2/Ang-1 ratio above which
the risk of septic shock would increase in a non-linear
fashion. We dichotomized levels of Ang-2/Ang-1 into
median and cut-off values (estimated by the ROC proce-
dure), and calculated the relative risks of septic shock
development. The risk of septic shock was almost five
times greater among patients with Ang-2/Ang-1 ratio
exceeding the cut-off, even after adjustment for neutro-
phil and platelet counts (covariates with a P <0.1 in uni-
variate analysis) (Table 3).
Ang-2/Ang-1 ratio and 28-day sepsis-related mortality in
patients with FN
The relative risk of sepsis-related mortality for patients
with Ang-2/Ang-1 levels above the 5.0 cut-off was 5.8
(95% CI 1.96 to 17.59; P = 0.001) and 2.74 (95% confi-
dence interval, 1.054 to 7.160; P = 0.03) for Ang-2/Ang-
1 levels above the median. Using a Cox proportional-
hazards model, adjusting for neutrophil and platelet
count, the mortality risk was 4.20 (95% CI 1.60 to 11.05;
P = 0.004) for patients with an Ang-2/Ang-1 ratio above
5.0, and 2.73 (95% CI 0.97 to 7.75; P = 0.059) for
patients with an Ang-2/Ang-1 ratio above the median.
The Kaplan-Meier curves showed clear divergence of
survival estimates between patients with Ang-2/Ang-1
ratios above or below the median or cut-off values
(Figure 4).
Discussion
Among the several factors that contribute to a higher
risk of sepsis complications in patients with cancer, che-
motherapy-associated neutropenia is probably the sin-
gle-most important one [29]. Although the risk is higher
in patients with severe and long-lasting neutropenia,
risk stratification tools are limited, and the majority of
patients end up treated aggressively with hospitalization
and broad-spectrum antibiotics [29]. The most accepted
risk stratification tool for cancer-related FN is the
MASCC score [27]. However, this score offers limited
information for patients categorized as high-risk
(MASCC ≤21), which encompasses most patients sub-
mitted to more intensive myelotoxic chemotherapy pro-
tocols. Accordingly, management of patients with
cancer-related FN remains a challenging situation, for
which the availability of informative biomarkers would
be welcome.
In the last decade, mechanisms by which the endothe-
lial barrier is established in the embryo have been
described in detail [6]. As they were being described,
some authors demonstrated that the same mechanisms
were involved in the pathological disruption of the
endothelial barrier observed during sepsis [7]. Soon after
that, encouraging results were published about the use
of VEGF-A, sFlt-1, Ang-1 and Ang-2 as biomarkers of
septic shock development. In general, these studies
demonstrated a consistent pattern in patients with septic
shock, characterized by increased levels of proteins that
loosen endothelial cell junctions during vessel formation,
such VEGF-A and Ang-2, and decreased levels of barrier
stabilizing proteins, such as Ang-1. Indeed, imbalances
in Ang-1/Ang-2 ratio, expressed by a high Ang-2/Ang-1
ratio, recently emerged as one of the most promising
biomarkers for septic shock development in several
populations [11,16,30]. However, because patients with
cancer were excluded or underrepresented in these stu-
dies, it is not known whether these results may be
applied to patients with cancer.
In a preliminary study, we demonstrated that VEGF-A,
sFlt-1, Ang-1 and Ang-2 were associated with sepsis
severity in patients with FN [22,23]. So, the objective of
the present study was to validate the use of these bio-
markers in a larger and independent cohort of patients
with cancer and chemotherapy-associated FN, in experi-
mental conditions more closely mimicking the scenario
in which a sepsis biomarker would be ordered. This was
achieved by: (1) sequential enrollment of patients; (2)
limitation of exclusion criteria; (3) sample collection and
initial processing performed by hospital staff; and (4)
sampling time mimicking the local use of a biomarker
(CRP) already used for patients with FN [14].
Not infrequently, results obtained in well-designed
studies of diagnostic accuracy are not reproduced in
similar independent populations [31], due to differences
in time of sample collection and even in sample type
and manipulation. In fact, we were not able to confirm
previous reports of VEGF-A or sFlt-1 as informative
biomarkers of septic shock development in patients with
FN [23,32]. We speculate that these discrepancies are
associated with differences in the time-point of sample
Table 3 Relative risk of septic shock development
Chi-square test Multivariate analysis*














* Binary logistic regression
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collection, and with the potential influence of severe
neutropenia and thrombocytopenia in the variation of
VEGF-A, as neutrophils and platelets are major sources
of these mediator [33]. In addition, we cannot rule out
the possibility that differences in baseline levels of
VEGF-A between different types of malignancies [34]
could have also played a role. Whatever the reasons for
these discrepancies, they suggest that assays for VEGF-A
and sFlt-1 possibly lack the robustness required for a
sepsis biomarker to overcome the challenge of “real
world” conditions, based on our local-practice, in the
context of FN.
On the other hand, the main finding of our study was
the confirmation that the Ang-2/Ang-1 ratio is indepen-
dently associated with septic shock development in
patients with cancer and high-risk FN, for whom other
risk stratification tools provide very limited information.
Although it should be noted that the relatively low sen-
sitivity and specificity of the Ang-2/Ang-1 ratio do not
qualify it as a biomarker that could influence decision-
making by itself, it should also be pointed out that it
presented a higher estimated diagnostic accuracy than
CRP, Ang-1, Ang2 or the SOFA and MASCC scores,
with the latter being the most widely used risk stratifica-
tion tool for this population. In addition, the sensitivity
and specificity of the Ang-2/Ang-1 ratio was similar to
that of procalcitonin for the diagnosis of sepsis in criti-
cally ill patients [35]. Finally, our findings are important
not only because a biomarker with a negative predictive
value of 85% deserves to be evaluated as part of deci-
sion-making algorithms that incorporate clinical and
laboratory markers in patients with FN, but also because
they provide additional insights into the pathogenesis of
septic shock in this particular population.
The use of the Ang-2/Ang-1 ratio rather than Ang-2
as a biomarker has been a matter of recent debate [36].
As opposed to Ang-2, which is exclusively stored in
endothelial cells, Ang-1 is also expressed in platelets
Figure 4 Twenty-eight-day survival and septic shock development in high-risk FN patients. Kaplan-Meier estimates of 28-day (a) survival
and (b) septic shock development of patients with febrile neutropenia (FN) according to angiopoietin (Ang)-2/Ang-1 ratio. The ratio was
dichotomized by the median Ang-2/Ang-1 ratio (2.2) in all patients (right) or by an optimal cut-off level of 5.0 (left), defined by a receiver
operator characteristic (ROC) analysis.
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[37], so that ex vivo platelet activation can result in fal-
sely elevated Ang-1 levels, limiting the accuracy of the
Ang-2/Ang-1 ratio. Accordingly, the effect of pre-analy-
tical variables, such as sample type and manipulation,
have been cited as possible explanations for discrepant
results of Ang-1 levels as a sepsis biomarker [36]. On
the other hand, it is tempting to speculate that “true”
imbalances in Ang-1 and Ang-2 levels do represent a
biologically relevant determinant of endothelial barrier
integrity, as suggested by several lines of evidence [38].
It is not known whether the effect of ex vivo platelet
activation on Ang-1 levels is influenced by sample plate-
let count. However, our data showing a significant cor-
relation between platelet count and Ang-1 levels only in
patients with severe thrombocytopenia, but not in
patients with higher and more variable platelet counts,
suggest that severe hypoplastic thrombocytopenia could
attenuate the influence of the pre-analytical variables
that normally limit the determination of “true” Ang-1
levels. Therefore, although we acknowledge the technical
limitations of Ang-1 determination, we speculate that
more reliable Ang-1 levels can be obtained in patients
with chemotherapy-induced severe thrombocytopenia.
One of the main objectives of our study was to deter-
mine whether Ang-1 and Ang-2 measurements would
remain as relevant sepsis biomarkers in a population
with different characteristics than those from studies of
non-neutropenic patients. Neutrophils are critical com-
ponents of the innate immune response, releasing cyto-
kines and chemokines, engulfing pathogens and
contributing to microbial killing by a range of peptides
and by neutrophil extracellular trap formation [39]. It
was interesting to note that the optimal cut-off of the
Ang-2/Ang-1 ratio associated with septic shock in our
population was very similar to the mean peak Ang-2/
Ang-1 ratio observed in non-survivors in a study with
non-neutropenic sepsis patients (5.0 vs 5.4, respectively)
[11]. From a clinical standpoint, a significant difference
between our population and non-neutropenic patients is
the earlier collection of blood samples in the course of
infection, when clinical signs of sepsis were mild or
absent (as illustrated by the lower SOFA score in our
patients). The reason for this characteristic lies in the
fact that patients with FN are instructed to look for
medical care immediately after fever onset, allowing ear-
lier admission. In fact, we believe that the relatively
lower Ang-2 levels in our patients are another conse-
quence of this earlier evaluation. Of note, we have pre-
viously shown a five-fold increase in Ang-2 levels during
the first 48 hours of FN in patients that evolved to sep-
tic shock [22]. Another important difference in septic
shock between neutropenic and non-neutropenic
patients is the high frequency of invasive fungal infec-
tions (IFI) in the former group, often associated with a
protracted course of fever, and a longer time to septic
shock. In fact, although most of our patients evolved to
septic shock within a week from fever onset, four of the
five patients in whom septic shock developed from 7 to
17 days presented probable or proven IFI. Together, the
fact that a similar value of the Ang-2/Ang-1 ratio was
associated with worse outcomes in these two different
populations strengthens the concept that imbalances in
Ang-2 and Ang-1 concentrations are indeed a relevant
biomarker of septic shock development. Moreover, the
fact that imbalances in this pathway remain relevant for
the pathogenesis of septic shock in patients with severe
neutropenia indicates the independence of the Tie/
Angiopoietin pathway from neutrophil function during
sepsis. Indeed, this concept is reinforced by a series of
other recent studies showing that manipulation of
angiopoietin pathways can improve sepsis outcomes in
different animal models [15,40,41].
This study has several limitations. First, because of a
higher than expected coefficient of variation of VEGF-A
levels in our patients (CV% of 193%), and with only 20
patients with septic shock, our study had power to
detect only extreme differences of VEGF-A levels
between the outcome groups. Second, we did not evalu-
ate baseline Ang-2 levels. So, it is conceivable that dif-
ferences in Ang-2 levels present before chemotherapy,
which have been shown to be associated with disease-
free survival in high-risk myeloid malignancies [42],
might have influenced our results. Arguing against this
possibility is the fact that we and others have not found
significant differences in pre-chemotherapy Ang-2 levels
between different disease groups, even in cancers with
significant angiogenic activity, such as multiple myeloma
[22,42]. A third limitation refers to the importance of
the SOFA score as a readout of systemic organ failure
in our population, since thrombocytopenia was the only
category in which 61% of our patients scored, most of
them with high scores. Since thrombocytopenia in our
patients is simply a transient effect of chemotherapy, it
is fair to assume that the diagnostic accuracy of this
score is more limited in our population. We tried to
minimize this limitation by avoiding the use of the score
(mainly driven by thrombocytopenia) in our multivariate
analysis, in which platelet count had already been used
for adjustment. Fourth, we did not evaluate other out-
comes that have also been associated with alterations of
the Ang/Tie pathway, such as acute lung injury [43], so
that our results can only be applicable to the context of
septic shock development. Fifth, we did not control the
effect of fluid management, which has been shown to
influence Ang-2 levels [8], so that it is not possible to
exclude the idea that more aggressive fluid therapy could
have resulted in higher Ang-2 levels in some patients.
However, extreme values of Ang-2 were observed in both
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outcome groups, a consistent finding in studies with this
biomarker. Furthermore, fluid management before sample
collection was fairly standardized in our study. Last,
because three of our patients developed septic shock
between enrollment and sample collection, our study does
not support the use of the Ang-2/Ang-1 ratio as a predic-
tive tool, but rather as a biomarker of septic shock devel-
opment in a high-risk population.
Finally, we believe that an additional use of the Ang-2/
Ang-1 ratio in sepsis in the future could be the identifi-
cation of septic patient subgroups, in which disruption
of the endothelial barrier could play a more prominent
pathogenic role. In theory, the identification of these
more “leaky” patients could rationally guide the use of
new therapeutic strategies targeting pathways involved
in endothelial barrier regulation [13,44]. As targeted-
therapies directed to different pathogenic mechanisms
of sepsis begin to reach the phase of human clinical
trials, the availability of biomarkers capable of identify-
ing discrete patient subgroups among the highly hetero-
geneous population of patients with sepsis, could well
be the difference between failure and success of new
therapies for sepsis [4].
Conclusions
In conclusion, our study confirms that the measurement
of the Ang-2/Ang-1 ratio is a biomarker of septic shock
development in patients with cancer and chemotherapy-
related FN.
Key messages
• Ang-1 and And-2 are key regulators of endothelial
barrier integrity, and seem to be involved in the patho-
logical disruption of endothelial barrier during sepsis.
• Levels of Ang-1 and Ang-2 have been shown to be
promising biomarkers of septic shock development in
several populations, but not in cancer patients.
• A high Ang-2/Ang-2 ratio is independently asso-
ciated with septic shock development in patients with
cancer and chemotherapy-associated febrile neutropenia.
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